Tvardi News

Tvardi Therapeutics

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

HOUSTON, Texas, June 23, 2021 — Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with continued support and participation by existing …

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs Read More »

Tvardi Therapeutics

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

Houston, Texas. November 12, 2020 – Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, was recognized as one of the 10 Most Promising Life Science Companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is …

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum Read More »

Tvardi Therapeutics

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced the publication of preclinical studies establishing that its lead compound, TTI-101, is effective against treatment-resistant breast cancers. The paper, published in Clinical Cancer Research, elucidated the STAT3 pathway as the mechanism of resistance and demonstrated that TTI-101 overcame this resistance …

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers Read More »

Tvardi Therapeutics

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

Houston, TX. July 24, 2020 – Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced today its collaborators will receive over $5 million in non-dilutive grants to support the ongoing validation and clinical development of Tvardi’s lead compound, TTI-101. The three National Cancer Institute (NCI) funding …

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research Read More »

Tvardi Therapeutics

KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences

HOUSTON (1080 KRLD)- The majority of people who get the virus will get well without serious complications. Some may not even show symptoms. But a small minority, about five percent, do get seriously ill and require hospitalization. That group is at risk for developing pulmonary fibrosis, which is a scarring of the lungs. Dr. Ronald …

KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences Read More »

Tvardi Therapeutics

Biotech on the Rise

“Everything is bigger in Texas,” is a common refrain of Texans. And Houston does little to dispel the rumor currently ranked as the fourth largest city by population, and rising. Our city is known as the energy capital and hosts the Texas Medical Center (TMC), the largest medical complex in the world. Comprised of 58 …

Biotech on the Rise Read More »

Scroll to Top